പെഗിലേറ്റഡ് ലിപ്പോസോമൽ ഡോക്സോറൂബിസിൻ: ഹൃദയത്തിനുള്ള പാർശ്വഫലം കുറവുള്ള കാൻസറിനുള്ള മരുന്ന് Johnson Francis | August 1, 2025 | General Cardiology | No Comments Related Posts Breast arterial calcification a new risk marker for cardiovascular disease! No Comments | Mar 16, 2022 Radiation associated heart disease No Comments | Apr 13, 2013 Controversies in assessing and managing CVD risk in diabetics No Comments | Apr 22, 2012 DOACs vs. Warfarin: Understanding the Key Pharmacological Differences No Comments | Dec 21, 2025 About The Author Johnson Francis Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal